VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Immuno-Oncology 2022 | OpACIN-neo: TMB and IFN-γ identified as biomarkers of pathologic response in melanoma

Irene Reijers, Netherlands Cancer Institute, Amsterdam, The Netherlands, comments on findings from a biomarker analysis of the Phase II OpACIN-neo trial (NCT02977052), which assessed ipilimumab and nivolumab in stage III melanoma. High tumor mutational burden (TMB) and high interferon-gamma (IFN-γ) were both independently identified as biomarkers associated with pathologic response. A higher TMB was linked to improved major pathologic response, but did not affect 2-year event-free survival (EFS), whereas a higher IFN-γ was linked to better EFS. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter